FDA
-
-
-
-
-
-
-
EU panel backs Gilead's Trodelvy plus Keytruda for breast cancer
-
-
-
-
-
-
-
U.S. FDA Approves Trodelvy® for First-Line Treatment of Metastatic Triple-Negative Breast Cancer
-
-
-
-
-
-
-
Gilead and Merck announce successful HIV treatment trial results
-
-
-
-
-
-
-
Gilead’s Livdelzi® (Seladelpar) Delivers Statistically Significant Composite ALP Normalization in Phase 3 IDEAL Trial in Primary Biliary Cholangitis (PBC)
-
-
-
-
-
-
-
Gilead Receives CHMP Positive Opinion for Trodelvy® in First-Line Metastatic Triple-Negative Breast Cancer for Patients Not Candidates for PD-(L)1 Inhibitors
-
-
-
-
-
-
-
Gilead Sciences completes $7.8 billion Arcellx acquisition
-
-
-
-
-
-
-
Gilead Sciences to Acquire Ouro Medicines to Advance First in Class T Cell Engager Program for Autoimmune Diseases
-
330,341 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

